Effects on the Airway Lumen of Talsaclidine in Combination With Propranolol in Comparison to the Effects of the Monosubstances in Healthy Elderly Male Volunteers

NCT ID: NCT02264093

Last Updated: 2014-10-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1999-11-30

Brief Summary

To investigate the effects on airway lumen of talsaclidine in combination with propranolol and of talsaclidine and propranolol given as monosubstances

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Talsaclidine with Propranol

Group Type: EXPERIMENTAL

Propranolol

Intervention Type: DRUG

Talsaclidine

Intervention Type: DRUG

Propranolol

Group Type: ACTIVE_COMPARATOR

Propranolol

Intervention Type: DRUG

Talsaclidine

Group Type: ACTIVE_COMPARATOR

Talsaclidine

Intervention Type: DRUG

Interventions

Propranolol

Intervention Type: DRUG

Talsaclidine

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

All participants in the study should be healthy males, range from 50 to 65 years of age and be within +- 20% of their normal weight (Broca-Index).

Exclusion Criteria

• Volunteers will be excluded from the study if the result of the medical examination or laboratory tests (especially those which indicate liver malfunction) are judged by the clinical investigator to differ significantly from the normal clinical values
• Volunteers with blood pressure lower than 120/80 mm Hg or pulse rate below 60 beats/min
• Volunteers whose blood pressure dropped below 100/60 mm Hg in the pre-test within 80 mg propranolol
• Volunteers with Raw-values higher than their predicted normal upper limit
• Volunteers with known gastrointestinal, hepatic , renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
• Volunteers with disease of the central nervous system (such as epilepsy) or with psychiatric disorders
• Volunteers with known history of orthostatic hypotension, fainting spells or blackouts
• Volunteers with chronic or relevant acute infections
• Volunteers with history of allergy / hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
• Volunteers who have taken a drug with a long half life (>=24 hours) within at least one month or less than ten half lives of the respective drug before enrolment in the study
• Volunteers who received any other drugs which might influence the results of the trial during the week prior the start of the study
• Volunteers who have participated in another study with an investigational drug within the last 2 month preceding this study
• Volunteers who are unable to refrain from smoking on the study days
• Volunteers who smoke more than 10 cigarettes (or 3 cigars or pipes) per day
• Volunteers who drink more than 40 g of alcohol per day
• Volunteers who are dependent on drugs
• Volunteers who have donated blood (>=100ml) within the last 4 weeks
• Volunteers who participated in excessive physical activities (e.g. competitive sports) within the last week before the study

• Minimum Eligible Age: 50 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Boehringer Ingelheim

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

506.114

Identifier Type: -

Identifier Source: org_study_id